Skip to main content
Clinical Trials/NCT04367688
NCT04367688
Completed
N/A

Delivery of Pre-exposure Prophylaxis to Individuals With High Sexual Risk of HIV Infection in Hong Kong - an Implementation Study

Chinese University of Hong Kong1 site in 1 country339 target enrollmentMarch 1, 2020
ConditionsHIV Infections

Overview

Phase
N/A
Intervention
Not specified
Conditions
HIV Infections
Sponsor
Chinese University of Hong Kong
Enrollment
339
Locations
1
Primary Endpoint
adherence to PrEP service
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

While pre-exposure prophylaxis (PrEP) is widely recommended and a number of pilot studies are on-going worldwide, progress of its implementation in the real world setting has been slow, especially in Asia. This study aims to develop a service model for PrEP delivery and test its operability in the real world setting. In this implementation study, 400 individuals with high sexual risk of HIV infection who fulfil eligibility criteria would be recruited. Eligible participants would receive one year of daily tenofovir disoproxil fumarate 300mg / emtricitabine 200mg (TDF/FTC) for free. A client-initiated approach would be adopted, requiring participants to self-arrange for regular HIV/sexually transmitted infections (STI) testing. An online system would be developed to facilitate participants to plan for testing and consultation for accessing PrEP. Questionnaire at baseline and subsequent monthly follow-up would be administered to assess behaviour, monitor adverse effects and drug adherence, the latter coupled with the completion of an online diary. Testing of HIV and creatinine would be performed using point-of-care test or by phlebotomy during clinical visits. Blood samples would be collected for archiving. Around 40 participants would be invited to join an in-depth interview in the later part of the study to evaluate the service model. The main outcome measures are: PrEP service adherence, PrEP drug adherence, prevalence of drug intolerance, prevalence of unprotected sex in the study period, incidence of HIV and STI

Registry
clinicaltrials.gov
Start Date
March 1, 2020
End Date
January 31, 2024
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Shui-Shan Lee, MD

Professor

Chinese University of Hong Kong

Eligibility Criteria

Inclusion Criteria

  • Can communicate in written and spoken English or Chinese
  • Is normally resident in Hong Kong
  • Has tested HIV antibody negative in the past 3 months
  • Has more than 1 episode of unprotected sex (especially anal sex) in the preceding 6 months
  • Has any one of the following experiences in the past 6 months: chemsex engagement, group sex, multiple sex partners, STI diagnosis, having sex partner(s) with HIV+ve status
  • Is inclined to engage in high risk sexual activities

Exclusion Criteria

  • Chronic HBV infection (HBsAg +ve)
  • Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \< 60mL/min/1.73m2
  • Having any form of mental illnesses
  • Inability or refusal to give consent
  • Prisoners or any institutionalised persons
  • Pregnant or planning to get pregnant (for female)
  • Injection drug user

Outcomes

Primary Outcomes

adherence to PrEP service

Time Frame: 12 months

attending the PrEP service with prescription and HIV tests regularly in accordance with protocol

adherence to PrEP regimen

Time Frame: 12 months

proportion adherent to daily TDF/FTC

Study Sites (1)

Loading locations...

Similar Trials